Company profile
Scorpius Holdings, Inc.
OTC: SCPX · Healthcare · Biotechnology
#689 of 1,422 Healthcare companies by revenue31st-percentile growth
EA Score
——FH —DQ 28GM —SS 45
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, workforce scale · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$3.8M
Rev growth YoY (TTM)
-62.5%
Net income (FY)
-$32.8M
Employees
91
as of 2026-08-29
Market cap
$26.0k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.2M$6.2M2024
Net income-$32.8M-$32.8M2024
Operating income-$33.6M-$33.6M2024
Total assets$39.2M$39.2M2024
Liabilities$37.5M$37.5M2024
Equity$6.3M$6.3M2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY19
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Scorpius Holdings, Inc.’s revenue?
Scorpius Holdings, Inc. booked $6.2M in FY2024 revenue, contracting 11% year over year — slower than 69% of Healthcare companies we track, at a -525.5% net margin.
Peers · Healthcare
Korro Bio, Inc.41DHTG Molecular Diagnostics, Inc.——Jack Nathan Medical Corp.——Decision Diagnostics Corp.——bioAffinity Technologies, Inc.32DOracle Healthcare Acquisition Corp.——Neighbors
Bexar →Key facts
CEOJeff A. Wolf
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Antonio, TX
ExchangeOTC: SCPX
Employees91
IPO date2013-07-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.